YM BIOSCIENCES NIMOTUZUMAB PRESENTATIONS AT ASCO 2008
May 06 2008 - 3:01AM
UK Regulatory
YM BIOSCIENCES ANNOUNCES SCHEDULE OF NIMOTUZUMAB PRESENTATIONS AT ASCO 2008
ANNUAL MEETING
MISSISSAUGA, ON, May 5 /CNW/ - YM BioSciences Inc. (AMEX: YMI, TSX: YM,
AIM: YMBA), an oncology company that identifies, develops and commercializes
differentiated products for patients worldwide, today announced that posters
describing research conducted on its anti-cancer drug nimotuzumab are
scheduled to be presented at the 2008 American Society of Clinical Oncology
(ASCO) Annual Meeting, which takes place May 30 - June 3, 2008 in Chicago, IL.
The first poster presentation, entitled "Phase III trial of nimotuzumab
for the treatment of newly diagnosed diffuse intrinsic pontine gliomas in
children and adolescents" is listed as scheduled to be presented on Sunday,
June 1, 2008 from 2:00 pm to 6:00 pm. (S Hall A1, Poster Board number 3D,
Abstract number 2058)
The second poster presentation, entitled "Pharmacodynamic (PD) study of
Nimotuzumab, an anti epidermal growth factor receptor (EGFR) monoclonal
antibody (MAb), in patients with unresectable squamous cell carcinoma of the
head and neck (SCCHN): A SENDO Foundation study" is scheduled to be presented
on Saturday, May 31, 2008 from 2:00 pm to 6:00 pm. (S Hall A1, Poster Board
number 14D, Abstract number 6070)
The third poster presentation, entitled "Preliminary results of an
escalating dose phase I clinical trial of the anti-EGFR monoclonal antibody
nimotuzumab in combination with external radiotherapy in patients diagnosed
with stage IIb, III or IV non-small cell lung cancer unsuitable for radical
therapy" will be presented on Sunday, June 1, 2008 at 2:00 pm to 6:00 pm. (S
Hall A1, Poster Board number 15F, Abstract number 3037)
This poster will present updated trial results including survival data,
response rate and overall safety of nimotuzumab in the palliative patient
population.
The 2008 ASCO Annual Meeting abstracts will be publicly posted at
www.ASCO.org on Thursday, May 15th at 9:00PM EDT.
About YM BioSciences
YM BioSciences Inc. is an oncology company that identifies, develops and
commercializes differentiated products for patients worldwide. The Company has
two late-stage products: nimotuzumab, a humanized monoclonal antibody that
targets the epidermal growth factor receptor (EGFR) and is approved in several
countries for treatment of various types of head and neck cancer; and
AeroLEF(TM), a proprietary, inhaled-delivery composition of free and
liposome-encapsulated fentanyl in development for the treatment of moderate to
severe pain, including cancer pain.
This press release may contain forward-looking statements, which reflect
the Company's current expectation regarding future events. These
forward-looking statements involve risks and uncertainties that may cause
actual results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Such factors include, but are not limited to,
changing market conditions, the successful and timely completion of clinical
studies, the establishment of corporate alliances, the impact of competitive
products and pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to time in the
Company's ongoing quarterly and annual reporting. Certain of the assumptions
made in preparing forward-looking statements include but are not limited to
the following: that nimotuzumab will continue to demonstrate a competitive
safety profile in ongoing and future clinical trials; that AeroLEF(TM) will
continue to generate positive efficacy and safety data in future clinical
trials; and that YM and its various partners will complete their respective
clinical trials within the timelines communicated in this release. We
undertake no obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise.
For further information: Thomas Fechtner, the Trout Group LLC, Tel. (646)
378-2931, Email: tfechtner(at)troutgroup.com; James Smith, the Equicom Group
Inc., Tel. (416) 815-0700 x 229, Email: jsmith(at)equicomgroup.com; Nominated
Adviser, Canaccord Adams Limited, Ryan Gaffney, Tel. +44 (0)20 7050 6500
(YM. YMI)
END
YM Bio.'b'ser1 (LSE:YMB)
Historical Stock Chart
From Jun 2024 to Jul 2024
YM Bio.'b'ser1 (LSE:YMB)
Historical Stock Chart
From Jul 2023 to Jul 2024